Long-Term Debt (Quarterly)

Long-Term Debt: The sum of all long term debt fields.

Valeant Pharmaceuticals International Inc. (T.BHC) Long-Term Debt data is not available.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	--
Net Income	204.73M
Cost of Goods Sold	--
Gross Profit	--
Operating Expenses	--
Operating Income	614.19M
Non-Operating Income/Expense	--
Pre-Tax Income	193.66M
Normalized Pre-Tax Income	193.66M
Income after Taxes	177.06M
Income from Continuous Operations	177.06M
Consolidated Net Income/Loss	177.06M
Normalized Income after Taxes	177.06M
EBIT	614.19M
EBITDA	1.08B
Weighted-Average Shares Outstanding (Basic)	370.90M
Weighted-Average Shares Outstanding (Diluted)	373.10M
Earnings per Share (EPS) (Basic)	0.55
Earnings per Share (EPS) (Diluted)	0.55
Balance Sheet Financials
Current Assets	--
Property, Plant, and Equipment	--
Long-Term Assets	--
Total Assets	37.72B
Current Liabilities	--
Long-Term Debt	--
Long-Term Liabilities	--
Total Liabilities	37.51B
Common Equity	203.35M
Tangible Shareholders Equity	-22.41B
Shareholders Equity	203.35M
Common Shares Outstanding	369.75M
Cash Flow Statement Financials
Cash Flow from Operating Activities	691.65M
Cash Flow from Investing Activities	-318.16M
Cash Flow from Financial Activities	293.26M
Beginning Cash	1.66B
End Cash	2.41B
Increase/Decrease in Cash	749.75M
Stock-Based Compensation	123.11M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.31
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.99
Debt to Equity Ratio	147.88
Gross Margin	69.80%
Operating Margin	17.55%
EBIT Margin	17.55%
EBITDA Margin	--
Pre-Tax Profit Margin	5.53%
Profit Margin	5.85%
Free Cash Flow	395.62M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.09
Inventory Turnover	0.46
Receiveable Turnover	1.14
Days Sales in Receivables	78.62
Return on Equity	87.07%
Return on Tangible Equity	-0.79%
Return on Assets	0.47%
Return on Investments	0.61%
Book Value Per Share	0.55
Free Cash Flow per Share	1.06
Operating Cash Flow per Share	1.85

Data from Zacks Investment Research, Inc.